Welcome
The BCLC at the Hospital Clínic of Barcelona is a multidisciplinary team involving all relevant medical specialities devoted to clinical care, research and education in the field of liver cancer. It combines state of the art diagnosis and therapy, with the development of several research projects to evaluate new treatment options. These include laboratory studies in cell cultures or animal models and clinical trials in patients with liver cancer.


Short term fellowships
Recent Publications

JOURNAL ARTICLE
Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success
Da Fonseca LG, Reig M, 
Bruix J

Oncotarget 2018;9:33741-33742
Pubmed abstract
JOURNAL ARTICLE
Liver Metastases From Gastric Adenocarcinoma Mimicking Multinodular Hepatocellular Carcinoma
Díaz-González Á, Monclús E, Darnell A, Solé M, 
Bruix J

Hepatology 2018;68:2042-2044
Pubmed abstract
JOURNAL ARTICLE
Should patients with NAFLD/NASH be surveyed for HCC?

Reig M
, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, Toso C

Transplantation 2018;:doi: 10.1097/TP.0000000000002361
Pubmed abstract
JOURNAL ARTICLE
Locoregional versus systemic therapy - robust positive data remain elusive

Sanduzzi-Zamparelli M, 
Bruix J

Nat Rev Clin Oncol. DOI: 10.1038/s41571-018-0047-6;
Pubmed abstract
JOURNAL ARTICLE
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: additional analyses from the phase 3 RESORCE trial.

Finn RS, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Gerolami R, Caparello C, Cabrera R, Chang C, Sun W, LeBerre MA, Baumhauer A, Meinhardt G, 
Bruix J J Hepatology 2018;:10.1016/j.jhep.2018.04.010
Pubmed abstract
JOURNAL ARTICLE
Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.

Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC, Marí M, Colell A, 
Bruix J, Morales A. Oncotarget 2018;24:16701-16717
Pubmed abstract